

## CLEO Further Expands Ovarian Cancer Trial with Siles Health

### Highlights

- **Prominent women's ultrasound specialist Siles Health joins CLEO's ovarian cancer trial**
- **Inclusion of Siles will provide important insights to support clinical implementation strategies for market adoption of CLEO's ovarian cancer blood test**

MELBOURNE, AUSTRALIA, 10 December 2024: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce further expansion of clinical trial sites for its simple and accurate blood test for the early detection of ovarian cancer.

### Further Expansion of Clinical Trials

CLEO has expanded its ovarian cancer Australian trial to include Siles Health network of 13 clinics across Melbourne and regional Victoria. Siles Health is a prominent women's health and ultrasound specialist, with Associate Professor Charles Siles, acting as Principal Investigator. The collaborative partnership aims to:

- provide important insights into clinical workflows that will ultimately support clinical implementation strategies for successful market adoption of CLEO's ovarian cancer blood test;
- supplement CLEO's broader trial strategy by accessing a larger cohort of patient samples that may bolster the FDA-enabling U.S. trial;
- continue to expand broader market awareness for CLEO; and
- verify and optimise CLEO's ovarian cancer blood test.

### Commenting on the partnership, Associate Professor Charles Siles, Founder of Siles Health, said:

*"The opportunity to collaborate with Cleo Diagnostics on their ovarian cancer diagnostics technology reflects our shared commitment to advancing women's health. We see the unmet clinical need every day therefore we are genuinely excited that CLEO's ovarian cancer blood test has the potential to positively impact women's lives through accurate and early diagnosis."*

### CLEO Chief Executive, Richard Allman, added:

*"As we progress through our clinical trials initiatives, our focus continues on how this ultimately supports successful market adoption of CLEO's ovarian cancer blood test, specifically in the U.S. as our first market in the next year.*

*In this context, the partners that CLEO is engaging play an important role in how the Company is executing on its ambition to transform ovarian cancer diagnostics."*

#### Cleo Diagnostics Ltd ASX:COV

Level 2, 480 Collins Street, Melbourne, VIC, 3000  
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com

#### Directors

Chair and Non-Executive Director **Adrien Wing**  
Chief Executive Officer and Executive Director **Dr Richard Allman**  
Chief Scientific Officer and Executive Director **Dr Andrew Stephens**  
Non-Executive Director and Lead Medical Advisor **Professor Tom Jobling**  
Non-Executive Director **Lucinda Nolan**

**-ENDS-**

**This ASX announcement was authorised for release on behalf of the Cleo Diagnostics Ltd Board by:**  
Richard Allman, Chief Executive Officer.

For more information, contact:

**Richard Allman**  
Chief Executive Officer  
+613 9614 0600  
office@cleodx.com

**Elvis Jurcevic**  
Investor Relations  
+614 08 268 271  
ej@cleodx.com

Forward Looking Statements: This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Cleo and certain of the plans and objectives of Cleo with respect to these items. These forward-looking statements are not historical facts but rather are based on Cleo's current expectations, estimates and projections about the industry in which Cleo operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Cleo, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Cleo cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Cleo only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Cleo will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

#### **About Cleo Diagnostics Ltd** ASX:COV

CLEO aims to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in non-malignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide.

The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted with over 500 patients. Pursuant to a licence agreement with the Hudson Institute of Medical Research, CLEO has a worldwide exclusive licence to commercialise the intellectual property which underpins its operations and the ovarian cancer tests.

The clinical unmet worldwide need is urgent. An accurate and early detection blood test could shift survivability for ovarian cancer significantly as seen with other cancers. CLEO is advancing the availability of its simple blood test, under a modular execution strategy which is designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.

